A risk prediction model of sperm retrieval failure with fine needle aspiration in males with non-obstructive azoospermia.


Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 28 07 2018
accepted: 08 12 2018
pubmed: 24 12 2018
medline: 20 6 2020
entrez: 22 12 2018
Statut: ppublish

Résumé

Can we predict the risk of sperm retrieval failure among men with non-obstructive azoospermia (NOA) before they undergo fine needle aspiration (FNA)? Our model, which includes FSH level, age and testicular volume as variables, can predict the risk of sperm retrieval failure with FNA. Combined with ICSI, testicular sperm aspiration (TESA) can enable patients with NOA to have their own genetic offspring. Nearly all reproductive medicine centres in China have applied FNA, but approximately half of patients with NOA experience testicular sperm retrieval failure. Nevertheless, the models developed to predict the likelihood of obtaining spermatozoa with testicular sperm extraction (TESE) cannot accurately predict sperm retrieval, and few of these models have been sufficiently validated. This study involved three cohorts including 597 men with NOA. From 1 January 2015 to 31 July 2017, a retrospective cohort of 317 males with NOA who underwent FNA procedures at a university affiliated hospital were included to build a risk prediction model of sperm retrieval failure with FNA. Then, from 25 October 2017 to 31 March 2018, two prospective cohorts of 61 and 219 males with NOA from the same hospital and one other reproductive specialist hospital respectively, were recruited to validate the risk prediction model. All men with NOA undergoing their first TESE procedure as part of a fertility treatment were included. The primary end-point was the presence of one or more spermatozoa (regardless of their motility) obtained with FNA. A binary multivariable logistic model was built to predict the risk of sperm retrieval failure after TESA using the dataset from the retrospective cohort. A cut-off value for risk was calculated with receiver operating characteristic (ROC) curve analysis. Two validation sets from the prospective cohort were used to validate the risk prediction model by measures including prediction accuracy and the true positive rate. A total of 327 (54.8%) males with NOA experienced sperm retrieval failure with FNA. FSH level, age and testicular volume were included in the prediction model for sperm retrieval failure risk. The model had an AUC of 82.3% (95% CI: 77.6-87.1%) and a cut-off value of 64.61% with a sensitivity of 0.677 and specificity of 0.863 for predicted risk. The predictive accuracies were 85.25 and 83.56% in the external validation sets from two centres. Specifically, 85.71 and 85.15% of NOA patients from two centres that experienced sperm retrieval failure were correctly identified using our model. A small proportion of males with NOA in whom sperm were successfully retrieved with FNA were misclassified; therefore, TESA techniques with higher sperm retrieval rates may be attempted in patients with high predicted risks of sperm retrieval failure rather than terminating the efforts to produce a genetic offspring. In addition, the ability to achieve a live birth using sperm retrieved with FNA was not tested in this study. We would recommend the use of micro-TESE for men with NOA and a high predicted risk of FNA failure. This study was partly supported by National Key R&D Program of China (No. 2017YFC0907305), the National Natural Science Foundation of China (No.81803332), Sichuan Science & Technology Program (No. 2018SZ0144, 2016SZ0066, 2018SZ0284 and 2018FZ0043), Chengdu Science & Technology Bureau (No. 2018-YF05-01265-SN), Postdoctoral Research foundation of Sichuan University (No. 2018SCU12012) and West China Second University Hospital of Sichuan University (No. kx027). There are no competing interests related to this study. Not applicable.

Identifiants

pubmed: 30576444
pii: 5253927
doi: 10.1093/humrep/dey366
pmc: PMC6343465
doi:

Substances chimiques

Testosterone 3XMK78S47O

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

200-208

Références

Hum Reprod. 1999 Jan;14(1):131-5
pubmed: 10374109
Hum Reprod. 1999 Jul;14(7):1785-90
pubmed: 10402390
Hum Reprod. 2000 Nov;15(11):2356-9
pubmed: 11056132
J Urol. 2003 Oct;170(4 Pt 1):1287-90
pubmed: 14501743
J Urol. 2004 Jun;171(6 Pt 1):2354-7
pubmed: 15126820
J Urol. 2004 Nov;172(5 Pt 1):1944-7
pubmed: 15540761
Urology. 2005 Jun;65(6):1190-4
pubmed: 15922422
Int J Urol. 2007 Oct;14(10):883-9
pubmed: 17880285
Fertil Steril. 2009 Apr;91(4):963-70
pubmed: 19304289
Fertil Steril. 2010 Nov;94(6):2157-60
pubmed: 20172512
Hum Reprod Update. 2010 Nov-Dec;16(6):713-24
pubmed: 20601364
Reprod Biol Endocrinol. 2010 Sep 08;8:108
pubmed: 20825644
Asian J Androl. 2011 Mar;13(2):225-30
pubmed: 21258355
Hum Reprod. 2011 Dec;26(12):3215-21
pubmed: 21930531
J Urol. 2012 Aug;188(2):558-9
pubmed: 22784761
Zhonghua Nan Ke Xue. 2012 Jul;18(7):606-10
pubmed: 22994045
Asian J Androl. 2013 Jan;15(1):35-9
pubmed: 23241638
J Urol. 2013 Feb;189(2):638-42
pubmed: 23260551
J Urol. 2014 Jan;191(1):175-8
pubmed: 23911635
Urol J. 2014 Sep 06;11(4):1825-8
pubmed: 25194084
Asian J Androl. 2015 Mar-Apr;17(2):281-4
pubmed: 25337843
J Urol. 2015 Apr;193(4):1318-21
pubmed: 25444960
Fertil Steril. 2015 Nov;104(5):1099-103.e1-3
pubmed: 26263080
BMC Urol. 2016 May 12;16(1):20
pubmed: 27176005
Hum Reprod. 2016 Sep;31(9):1934-41
pubmed: 27406950
Beijing Da Xue Xue Bao Yi Xue Ban. 2018 Aug 18;50(4):613-616
pubmed: 30122758
Urology. 1997 May;49(5):743-8
pubmed: 9145981

Auteurs

Yue Ma (Y)

West China School of Public Health and Healthy Food Evaluation Research Center, Sichuan University, Chengdu, Sichuan, China.

Fuping Li (F)

Human Sperm Bank, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.

Li Wang (L)

Jinjiang Maternity and Child Health Hospital, Chengdu, Sichuan, China.

Wenrui Zhao (W)

Human Sperm Bank, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.

Dingming Li (D)

Human Sperm Bank, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.

Yang Xian (Y)

Human Sperm Bank, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.

Xiaohui Jiang (X)

Human Sperm Bank, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH